| Autor: |
Mathé, G., Amiel, J.L., Schwarzenberg, L., Schneider, M., Cattan, A., Schlumberger, J.R., Hayat, M., De Vassal, F. |
| Zdroj: |
The Lancet; April 1969, Vol. 293 Issue: 7597 p697-699, 3p |
| Abstrakt: |
Active immunotherapy (with B.C.G. and/or vaccination from a pool of allogeneic leukæmic " lymphoblasts " pretreated with formalin or irradiated in vitro) has been given to patients with acute lymphoblastic leukæmia who had previously been treated by chemotherapy, to induce a remission, and by complementary chemotherapy designed to reduce the number of tumour cells. Ten patients were not treated by immunotherapy after stopping chemotherapy: they have all relapsed. Out of twenty patients treated by immunotherapy, eight have not relapsed (and remissions have now passed 295 days after stopping chemotherapy, the longest remission being 1150 days so far). These results demonstrate the efficacy of active immunotherapy in the control of acute lymphoblastic leukæmia in man. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
